P-糖蛋白抑制剂在PET显像中的应用研究

何燕; 苏晋; 郑晓霞; 温莉; 孙树兰; 何燕; 苏晋; 郑晓霞; 温莉; 孙树兰

doi:10.3760/cma.j.issn.1673-4114.2016.01.001

[1]

应帅, 郑婷婷, 陈培远, 等.BCRP/ABCG2的结构功能及相关抑制剂研究[J].中国医药生物技术, 2013, 8(3):201-205.DOI:10.3969/cmba.j.issn.1673-713X.2013.03.009.
Ying S, Zheng TT, Chen PY, et al.Study on the structure and function of BCRP/ABCG2 and its related inhibitors[J].Chin Med Biotechnol, 2013, 8(3):201-205. doi: 10.3969/cmba.j.issn.1673-713X.2013.03.009

[2]

Luurtsema G, Schuit RC, Klok RP, et al.Evaluation of[¹¹C]laniquidar as a tracer of P-glycoprotein:radiosynthesis and biodistribution in rats[J].Nucl Med Biol, 2009, 36(6):643-649.DOI:10.1016/j.nucmedbio.2009.03.004.

[3]

Zhou S, Schuetz JD, Bunting KD, et al.The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype[J].Nat Med, 2001, 7(9):1028-1034.DOI:10.1038/nm0901-1028.

[4]

Hubensack M, Mueller C, Hoecherl PA, et al.Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice[J].J Cancer Res Clin Oncol, 2008, 134(5):597-607.DOI:10.1007/s00432-007-0323-9.

[5]

Ikoma Y, Takano A, Ito H, et al.Quantitative analysis of ¹¹C-verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function[J].J Nucl Med, 2006, 47(9):1531-1537.

[6]

Aller SG, Yu J, Ward A, et al.Structure of P-Glycoprotein reveals a molecular basis for Poly-Specific drug binding[J].Science, 2009, 323(5922):1718-1722.DOI:10.1126/science.1168750.

[7]

Maliepaard M, Scheffer GL, Faneyte IF, et al.Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues[J].Cancer Res, 2001, 61(8):3458-3464.

[8]

郁春景, 吴翼伟, 万卫星.P-gp功能的PET显像剂的研究进展[J].国际放射医学核医学杂志, 2014, 38(6):403-407.DOI:10.3760/cma.j.issn.1673-4114.2014.06.013.
Yu CJ, Wu YW, Wan WX.Progress in PET imaging evaluating of P-gp function[J].Inter J Radiat Med Nucl Med, 2014, 38(6):403-407. doi: 10.3760/cma.j.issn.1673-4114.2014.06.013

[9]

戴春玲, 吴翼伟, 万卫星.P-gp功能的PET显像剂的研究进展[J].中国药理学通报, 2005, 21(5):513-518.DOI:10.3321/j.issn:1001-1978.2005.05.001.
Dai CL, Wu YW, Wan WX.The development of the reversal of the tumor multidrug fesistance[J].Chin Pharmacol Bull, 2005, 21(5):513-518. doi: 10.3321/j.issn:1001-1978.2005.05.001

[10]

Nicolazzo JA, Katneni K.Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein(ABCG2)[J].Curr Top Med Chem, 2009, 9(2):130-147.DOI:10.2174/156802609787521580.

[11]

Jonker JW, Freeman J, Bolscher E, et al.Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice[J].Stem Cells, 2005, 23(8):1059-1065.DOI:10.1634/stemcells.2005-0150.

[12]

Kawamura K, Yamasaki T, Yui J, et al.In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [¹¹C] gefitinib[J].Nucl Med Biol, 2009, 36(3):239-246.DOI:10.1016/j.nucmedbio.2008.12.006.